February 18, 2022
Life Sciences
  • The Federal Trade Commission (FTC) will not move forward with a study examining how pharmacy benefit managers’ (PBMs) controversial business practices affect independent and specialty pharmacies. The commissioners tied in a 2-2 vote over an effort to broaden the study to include rebates. The decision angered pharmacy groups, which say PBMs hurt local competition and impose opaque fees that inflate drug prices. One analyst said it’s likely the FTC will return to the issue. (Articles here and here)